Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer

FASEB Journal

Volumn 29, Issue 2, 2015, Pages 576-588

  Russell, Samantha ^a   Duquette, Mark ^b   Liu, Joyce ^b   Drapkin, Ronny ^b   Lawler, Jack ^b   Petrik, Jim ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiangiogenic; Metronomic; Vessel normalization

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CD36 ANTIGEN; PROTEIN TYROSINE PHOSPHATASE SHP 1; THROMBOSPONDIN 1; THROMBOSPONDIN 1 TYPE I REPEAT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; PTPN6 PROTEIN, MOUSE;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MORPHOMETRICS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE PERFUSION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; ANOXIA; C57BL MOUSE; CANCER TRANSPLANTATION; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL LINE;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ANTIGENS, CD36; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THROMBOSPONDIN 1; TREATMENT OUTCOME;

EID: 84937425239     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-261636     Document Type: Article

References (55)

1. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014) Cancer statistics, 2014. CA Cancer J. Clin. 64:252-271
2. Longuespée, R., Boyon, C., Desmons, A., Vinatier, D., Leblanc, E., Farré, I., Wisztorski, M., Ly, K., D'Anjou, F., Day, R., Fournier, I., and Salzet, M. (2012) Ovarian cancer molecular pathology. Cancer Metastasis Rev. 31, 713-732
3. Vaughan, S., Coward, J. I., Bast, R. C., Jr., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., Friedlander, M., Gabra, H., Kaye, S. B., Lord, C. J., Lengyel, E., Levine, D. A., McNeish, I. A., Menon, U., Mills, G. B., Nephew, K. P., Oza, A. M., Sood, A. K., Stronach, E. A., Walczak, H., Bowtell, D. D., and Balkwill, F. R. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719-725
4. Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., and Kroemer, G. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883
5. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186
6. Zhou, M., Yu, P., Qu, X., Liu, Y., and Zhang, J. (2013) Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS ONE 8, e81858
7. Borofsky, S. E., Levine, M. S., Rubesin, S. E., Tanyi, J. L., Chu, C. S., and Lev-Toaff, A. S. (2013) Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom. Imaging 38, 265-272
8. Lawler, J., and Detmar, M. (2004) Tumor progression: the effects of thrombospondin-1 and -2. Int. J. Biochem. Cell Biol. 36,1038-1045
9. Zhang, J., Yang, W., Zhao, D., Han, Y., Liu, B., Zhao, H., Wang, H., Zhang, Q., and Xu, G. (2014) Correlation between TSP-1, TGF-beta and PPAR-gamma expression levels and glioma microvascular density. Oncol. Lett. 7, 95-100
10. Allegrini, G., Goulette, F. A., Darnowski, J. W., and Calabresi, P. (2004) Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother. Pharmacol. 53, 261-266
11. Zhang, X., Galardi, E., Duquette, M., Delic, M., Lawler, J., and Parangi, S. (2005) Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin. Cancer Res. 11, 2337-2344
12. Zhang, X., Xu, J., Lawler, J., Terwilliger, E., and Parangi, S. (2007) Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin. Cancer Res. 13, 3968-3976
13. Ren, B., Song, K., Parangi, S., Jin, T., Ye, M., Humphreys, R., Duquette, M., Zhang, X., Benhaga, N., Lawler, J., and Khosravi-Far, R. (2009) A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res. 69, 3856-3865
14. Zhang, X., Kazerounian, S., Duquette, M., Perruzzi, C., Nagy, J. A., Dvorak, H. F., Parangi, S., and Lawler, J. (2009) Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 23, 3368-3376
15. Lawler, J., and Hynes, R. O. (1989) An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood 74, 2022-2027
16. Calzada, M. J., Annis, D. S., Zeng, B., Marcinkiewicz, C., Banas, B., Lawler, J., Mosher, D. F., and Roberts, D. D. (2004) Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J. Biol. Chem. 279, 41734-41743
17. Short, S. M., Derrien, A., Narsimhan, R. P., Lawler, J., Ingber, D. E., and Zetter, B. R. (2005) Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J. Cell Biol. 168, 643-653
18. Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., and Bouck, N. (2000) Signals leading to apoptosisdependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6, 41-48
19. Chu, L. Y., Ramakrishnan, D. P., and Silverstein, R. L. (2013) Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells. Blood 122, 1822-1832
20. Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., Ribeiro, S. M., Lawler, J., Hynes, R. O., Boivin, G. P., and Bouck, N. (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93, 1159-1170
21. Pierce, D. F., Jr., Gorska, A. E., Chytil, A., Meise, K. S., Page, D. L., Coffey, R. J., Jr., and Moses, H. L. (1995) Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc. Natl. Acad. Sci. USA 92, 4254-4258
22. Miao, W. M., Seng, W. L., Duquette, M., Lawler, P., Laus, C., and Lawler, J. (2001) Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res. 61, 7830-7839
23. Campbell, N., Greenaway, J., Henkin, J., and Petrik, J. (2011) ABT-898 induces tumor regression and prolongs survival in a mouse modelofepithelialovariancancer. Mol. Cancer Ther. 10, 1876-1885
24. Gordon, M. S., Mendelson, D., Carr, R., Knight, R. A., Humerickhouse, R.A., Iannone, M., and Stopeck, A.T. (2008) A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113, 3420-3429
25. Recouvreux, M. V., Camilletti, M. A., Rifkin, D. B., Becu-Villalobos, D., and Díaz-Torga, G. (2012) Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1). Endocrinology 153, 3861-3871
26. Sahora, A. I., Rusk, A. W., Henkin, J., McKeegan, E. M., Shi, Y., and Khanna, C. (2012) Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. J. Vet. Intern. Med. 26, 1169-1176
27. Greenaway, J., Henkin, J., Lawler, J., Moorehead, R., and Petrik, J. (2009) ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol. Cancer Ther. 8, 64-74
28. Campbell, N. E., Greenaway, J., Henkin, J., Moorehead, R. A., and Petrik, J. (2010) The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 12, 275-283
29. Carmeliet, P., and Jain, R. K. (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427
30. Harries, M., and Gore, M. (2002) Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3, 537-545
31. Harries, M., and Gore, M. (2002) Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3, 529-536
32. Gately, S., and Kerbel, R. (2001) Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7, 427-436
33. Bocci, G., Fioravanti, A., Orlandi, P., Di Desidero, T., Natale, G., Fanelli, G., Viacava, P., Naccarato, A. G., Francia, G., and Danesi, R. (2012) Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1. Neoplasia 14, 833-845
34. Scharovsky, O. G., Mainetti, L. E., and Rozados, V. R. (2009) Metronomic chemotherapy: changing the paradigm that more is better. Curr. Oncol. 16, 7-15
35. Mayer, E. L., Isakoff, S. J., Klement, G., Downing, S. R., Chen, W. Y., Hannagan, K., Gelman, R., Winer, E. P., and Burstein, H. J. (2012) Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res. Treat. 136, 169-178
36. Kelley, R. K., Hwang, J., Magbanua, M. J., Watt, L., Beumer, J. H., Christner, S. M., Baruchel, S., Wu, B., Fong, L., Yeh, B. M., Moore, A. P., Ko, A. H., Korn, W. M., Rajpal, S., Park, J. W., Tempero, M.A., Venook, A.P., and Bergsland, E.K. (2013) A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br. J. Cancer 109, 1725-1734
37. Kamat, A. A., Kim, T. J., Landen, C. N., Jr., Lu, C., Han, L. Y., Lin, Y. G., Merritt, W. M., Thaker, P. H., Gershenson, D. M., Bischoff, F. Z., Heymach, J. V., Jaffe, R. B., Coleman, R. L., and Sood, A. K. (2007) Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 67, 281-288
38. Yee, K. O., Streit, M., Hawighorst, T., Detmar, M., and Lawler, J. (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am. J. Pathol. 165, 541-552
39. Clauss, A., Ng, V., Liu, J., Piao, H., Russo, M., Vena, N., Sheng, Q., Hirsch, M. S., Bonome, T., Matulonis, U., Ligon, A. H., Birrer, M. J., and Drapkin, R. (2010) Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 12, 161-172
40. Li, L., Wang, L., Zhang, W., Tang, B., Zhang, J., Song, H., Yao, D., Tang, Y., Chen, X., Yang, Z., Wang, G., Li, X., Zhao, J., Ding, H., Reed, E., and Li, Q. Q. (2004) Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24(3b), 1973-1979
41. Berkenblit, A., and Cannistra, S. A. (2005) Advances in the management of epithelial ovarian cancer. J. Reprod. Med. 50, 426-438
42. Greenaway, J., Moorehead, R., Shaw, P., and Petrik, J. (2008) Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol. Oncol. 108, 385-394
43. Dawson, D. W., Pearce, S. F., Zhong, R., Silverstein, R. L., Frazier, W. A., and Bouck, N. P. (1997) CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717
44. Horowitz, A., and Seerapu, H. R. (2012) Regulation of VEGF signaling by membrane traffic. Cell. Signal. 24, 1810-1820
45. Simons, M. (2012) An inside view: VEGF receptor trafficking and signaling. Physiology (Bethesda) 27, 213-222
46. Sher, I., Adham, S. A., Petrik, J., and Coomber, B. L. (2009) Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int. J. Cancer 124, 553-561
47. Adamcic, U., Skowronski, K., Peters, C., Morrison, J., and Coomber, B. L. (2012) The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia 14, 612-623
48. Yigit, R., Massuger, L. F., Figdor, C. G., and Torensma, R. (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol. Oncol. 117, 366-372
49. Dawson, D. W., Volpert, O. V., Pearce, S. F., Schneider, A. J., Silverstein, R. L., Henkin, J., and Bouck, N. P. (1999) Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 55, 332-338
50. Iruela-Arispe, M. L., Lombardo, M., Krutzsch, H. C., Lawler, J., and Roberts, D. D. (1999) Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100, 1423-1431
51. Tan, K., Duquette, M., Liu, J. H., Dong, Y., Zhang, R., Joachimiak, A., Lawler, J., and Wang, J. H. (2002) Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J. Cell Biol. 159, 373-382
52. Quesada, A. J., Nelius, T., Yap, R., Zaichuk, T. A., Alfranca, A., Filleur, S., Volpert, O. V., and Redondo, J. M. (2005) In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ. 12, 649-658
53. Yap, R., Veliceasa, D., Emmenegger, U., Kerbel, R. S., McKay, L. M., Henkin, J., and Volpert, O. V. (2005) Metronomic lowdose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin. Cancer Res. 11, 6678-6685
54. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J., and Bouck, N. (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity. J. Cell Biol. 122, 497-511
55. Uronis, H. E., Cushman, S. M., Bendell, J. C., Blobe, G. C., Morse, M. A., Nixon, A. B., Dellinger, A., Starr, M. D., Li, H., Meadows, K., Gockerman, J., Pang, H., and Hurwitz, H. I. (2013) A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med. 2, 316-324